727 related articles for article (PubMed ID: 30690729)
21. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
23. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
[TBL] [Abstract][Full Text] [Related]
24. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
26. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
27. Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.
You HL; Weng SW; Li SH; Wei YC; Sheu JJ; Chen CM; Huang WT
Exp Mol Pathol; 2012 Jun; 92(3):281-6. PubMed ID: 22366251
[TBL] [Abstract][Full Text] [Related]
28. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Simbolo M; Fassan M; Ruzzenente A; Mafficini A; Wood LD; Corbo V; Melisi D; Malleo G; Vicentini C; Malpeli G; Antonello D; Sperandio N; Capelli P; Tomezzoli A; Iacono C; Lawlor RT; Bassi C; Hruban RH; Guglielmi A; Tortora G; de Braud F; Scarpa A
Oncotarget; 2014 May; 5(9):2839-52. PubMed ID: 24867389
[TBL] [Abstract][Full Text] [Related]
29. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
[TBL] [Abstract][Full Text] [Related]
30. The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas.
Lee K; Lee KB; Jung HY; Yi NJ; Lee KW; Suh KS; Jang JJ
BMC Cancer; 2017 Jun; 17(1):441. PubMed ID: 28645247
[TBL] [Abstract][Full Text] [Related]
31. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
32. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
[TBL] [Abstract][Full Text] [Related]
33. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
[TBL] [Abstract][Full Text] [Related]
34. IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing.
Lee JH; Shin DH; Park WY; Shin N; Kim A; Lee HJ; Kim YK; Choi KU; Kim JY; Yang YI; Lee CH; Sol MY
World J Surg Oncol; 2017 Apr; 15(1):82. PubMed ID: 28403884
[TBL] [Abstract][Full Text] [Related]
35. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
[TBL] [Abstract][Full Text] [Related]
37. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
[TBL] [Abstract][Full Text] [Related]
38. Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma.
Sciarra A; Park YN; Sempoux C
Hum Pathol; 2020 Feb; 96():48-55. PubMed ID: 31931021
[TBL] [Abstract][Full Text] [Related]
39. Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma.
Huang XW; Huang Y; Chen LD; Wang Z; Yang Z; Liu JY; Xie XY; Lu MD; Shen SL; Wang W
J Med Ultrason (2001); 2018 Apr; 45(2):231-241. PubMed ID: 29052791
[TBL] [Abstract][Full Text] [Related]
40. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
